1
|
Teplitz GM, Lorenzo MS, Cruzans PR, Olea GB, Salamone DF, Bastien A, Robert C, Sirard MA, Lombardo DM. Coculture with porcine luteal cells during in vitro porcine oocyte maturation affects lipid content, cortical reaction and zona pellucida ultrastructure. Reprod Fertil Dev 2024; 36:NULL. [PMID: 38096792 DOI: 10.1071/rd23150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2023] [Accepted: 11/28/2023] [Indexed: 01/26/2024] Open
Abstract
CONTEXT In pigs, in vitro fertilisation (IVF) is associated with high polyspermy rates, and for this reason, in vitro embryo production (IVP) is still an inefficient biotechnology. Coculture with somatic cells is an alternative to improve suboptimal in vitro maturation (IVM) conditions. AIM This study was conducted to test a coculture system of porcine luteal cells (PLC) and cumulus-oocyte complexes (COC) to improve oocyte metabolism. METHODS COC were matured in vitro with PLC. Oocyte lipid content, mitochondrial activity, zona pellucida (ZP) digestibility and pore size, cortical reaction and in vitro embryo development were assessed. KEY RESULTS Coculture reduced cytoplasmic lipid content in the oocyte cytoplasm without increasing mitochondrial activity. Although ZP digestibility and ZP pore number were not different between culture systems, ZP pores were smaller in the coculture. Coculture impacted the distribution of cortical granules as they were found immediately under the oolemma, and more of them had released their content in the ZP. Coculture with porcine luteal cells during IVM increased monospermic penetration and embryo development after IVF. CONCLUSIONS The coculture of COC with PLC affects the metabolism of the oocyte and benefits monospermic penetration and embryo development. IMPLICATIONS The coculture system with PLC could be an alternative for the conventional maturation medium in pigs.
Collapse
Affiliation(s)
- G M Teplitz
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, Buenos Aires C1425FQB, Argentina; and Universidad de Buenos Aires, Facultad de Ciencias Veterinarias, Instituto de Investigación y Tecnología en Reproducción Animal, Cátedra de Histología y Embriología, Chorroarín 280, Buenos Aires C1427CWO, Argentina
| | - M S Lorenzo
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, Buenos Aires C1425FQB, Argentina; and Universidad de Buenos Aires, Facultad de Ciencias Veterinarias, Instituto de Investigación y Tecnología en Reproducción Animal, Cátedra de Histología y Embriología, Chorroarín 280, Buenos Aires C1427CWO, Argentina
| | - P R Cruzans
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, Buenos Aires C1425FQB, Argentina; and Universidad de Buenos Aires, Facultad de Ciencias Veterinarias, Instituto de Investigación y Tecnología en Reproducción Animal, Cátedra de Histología y Embriología, Chorroarín 280, Buenos Aires C1427CWO, Argentina
| | - G B Olea
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, Buenos Aires C1425FQB, Argentina; and Universidad Nacional del Nordeste, Facultad de Ciencias Veterinarias, Cátedra de Histología y Embriología, Cabral 2139, Corrientes C.P. 3400, Argentina
| | - D F Salamone
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, Buenos Aires C1425FQB, Argentina; and Laboratorio de Biotecnología Animal, Facultad de Agronomia, Universidad de Buenos Aires, Avenue San Martin 4453, Ciudad Autónoma de Buenos Aires C1417DSE, Argentina
| | - A Bastien
- Departement des Sciences Animales, Centre de Recherche en Reproduction, Développement et Santé Inter-générationnelle (CRDSI). Pavillon Des Services, local 2732, Université Laval, Québec, QC G1V 0A6, Canada
| | - C Robert
- Departement des Sciences Animales, Centre de Recherche en Reproduction, Développement et Santé Inter-générationnelle (CRDSI). Pavillon Des Services, local 2732, Université Laval, Québec, QC G1V 0A6, Canada
| | - M A Sirard
- Departement des Sciences Animales, Centre de Recherche en Reproduction, Développement et Santé Inter-générationnelle (CRDSI). Pavillon Des Services, local 2732, Université Laval, Québec, QC G1V 0A6, Canada
| | - D M Lombardo
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, Buenos Aires C1425FQB, Argentina; and Universidad de Buenos Aires, Facultad de Ciencias Veterinarias, Instituto de Investigación y Tecnología en Reproducción Animal, Cátedra de Histología y Embriología, Chorroarín 280, Buenos Aires C1427CWO, Argentina
| |
Collapse
|
2
|
Dogan S, Cournède PH, Solary E, Heard JM, Aldea M, Conroy T, Robert C, André F. Moving toward precision oncology centers V2.0. Ann Oncol 2023; 34:1088-1089. [PMID: 37805130 DOI: 10.1016/j.annonc.2023.09.3115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2023] [Revised: 09/15/2023] [Accepted: 09/18/2023] [Indexed: 10/09/2023] Open
Affiliation(s)
- S Dogan
- Gustave Roussy, INSERM U981, PRISM National Center for Precision Medicine, Villejuif
| | - P-H Cournède
- CentraleSupélec, Université Paris-Saclay, Laboratory of Mathematics and Informatics (MICS), Gif-sur-Yvette
| | - E Solary
- Gustave Roussy, INSERM U1287, Université Paris-Saclay, Equipe Labellisée Ligue Contre le Cancer, Villejuif; Department of Haematology, Gustave Roussy, Villejuif; Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicètre
| | - J-M Heard
- Gustave Roussy, INSERM U981, PRISM National Center for Precision Medicine, Villejuif
| | - M Aldea
- Gustave Roussy, INSERM U981, PRISM National Center for Precision Medicine, Villejuif; Department of Medical Oncology, Gustave Roussy, Villejuif
| | - T Conroy
- Medical Oncology Department, Institut de cancérologie de Lorraine, Vandoeuvre-lés-Nancy; Université de Lorraine, APEMAC, équipe MICS, Nancy, France
| | - C Robert
- Gustave Roussy, INSERM U981, PRISM National Center for Precision Medicine, Villejuif; Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicètre; Department of Medical Oncology, Gustave Roussy, Villejuif
| | - F André
- Gustave Roussy, INSERM U981, PRISM National Center for Precision Medicine, Villejuif; Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicètre; Department of Medical Oncology, Gustave Roussy, Villejuif.
| |
Collapse
|
3
|
Laillet J, Monnet P, Goldfarb L, Belkhir R, Robert C. Secondary hypertrophic osteoarthropathy revealing a metastatic melanoma. Eur J Cancer 2023; 192:113247. [PMID: 37625239 DOI: 10.1016/j.ejca.2023.113247] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2023] [Revised: 07/03/2023] [Accepted: 07/11/2023] [Indexed: 08/27/2023]
Affiliation(s)
- J Laillet
- Dermatology Department, Gustave Roussy Institute, Villejuif, France
| | - P Monnet
- Dermatology Department, Gustave Roussy Institute, Villejuif, France
| | - L Goldfarb
- Nuclear Medicine Department, Centre Hospitalier Fréderic Joliot, CEA, Orsay, France
| | - R Belkhir
- Rheumatology Department, FHU CARE, AP-HP-Hôpital Bicêtre, Paris-Saclay University, Le Kremlin Bicêtre, France
| | - C Robert
- Dermatology Department, Gustave Roussy Institute, Villejuif, France; Gustave Roussy and Paris Saclay University, Villejuif, France.
| |
Collapse
|
4
|
Clua-Provost T, Durand A, Mu Z, Rastoin T, Fraunié J, Janzen E, Schutte H, Edgar JH, Seine G, Claverie A, Marie X, Robert C, Gil B, Cassabois G, Jacques V. Isotopic Control of the Boron-Vacancy Spin Defect in Hexagonal Boron Nitride. Phys Rev Lett 2023; 131:126901. [PMID: 37802939 DOI: 10.1103/physrevlett.131.126901] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/17/2023] [Accepted: 08/26/2023] [Indexed: 10/08/2023]
Abstract
We report on electron spin resonance (ESR) spectroscopy of boron-vacancy (V_{B}^{-}) centers hosted in isotopically engineered hexagonal boron nitride (hBN) crystals. We first show that isotopic purification of hBN with ^{15}N yields a simplified and well-resolved hyperfine structure of V_{B}^{-} centers, while purification with ^{10}B leads to narrower ESR linewidths. These results establish isotopically purified h^{10}B^{15}N crystals as the optimal host material for future use of V_{B}^{-} spin defects in quantum technologies. Capitalizing on these findings, we then demonstrate optically induced polarization of ^{15}N nuclei in h^{10}B^{15}N, whose mechanism relies on electron-nuclear spin mixing in the V_{B}^{-} ground state. This work opens up new prospects for future developments of spin-based quantum sensors and simulators on a two-dimensional material platform.
Collapse
Affiliation(s)
- T Clua-Provost
- Laboratoire Charles Coulomb, Université de Montpellier and CNRS, 34095 Montpellier, France
| | - A Durand
- Laboratoire Charles Coulomb, Université de Montpellier and CNRS, 34095 Montpellier, France
| | - Z Mu
- Laboratoire Charles Coulomb, Université de Montpellier and CNRS, 34095 Montpellier, France
| | - T Rastoin
- Laboratoire Charles Coulomb, Université de Montpellier and CNRS, 34095 Montpellier, France
| | - J Fraunié
- Université de Toulouse, INSA-CNRS-UPS, LPCNO, 135 Avenue Rangueil, 31077 Toulouse, France
| | - E Janzen
- Tim Taylor Department of Chemical Engineering, Kansas State University, Manhattan, Kansas 66506, USA
| | - H Schutte
- Tim Taylor Department of Chemical Engineering, Kansas State University, Manhattan, Kansas 66506, USA
| | - J H Edgar
- Tim Taylor Department of Chemical Engineering, Kansas State University, Manhattan, Kansas 66506, USA
| | - G Seine
- CEMES-CNRS and Université de Toulouse, 29 rue J. Marvig, 31055 Toulouse, France
| | - A Claverie
- CEMES-CNRS and Université de Toulouse, 29 rue J. Marvig, 31055 Toulouse, France
| | - X Marie
- Université de Toulouse, INSA-CNRS-UPS, LPCNO, 135 Avenue Rangueil, 31077 Toulouse, France
| | - C Robert
- Université de Toulouse, INSA-CNRS-UPS, LPCNO, 135 Avenue Rangueil, 31077 Toulouse, France
| | - B Gil
- Laboratoire Charles Coulomb, Université de Montpellier and CNRS, 34095 Montpellier, France
| | - G Cassabois
- Laboratoire Charles Coulomb, Université de Montpellier and CNRS, 34095 Montpellier, France
| | - V Jacques
- Laboratoire Charles Coulomb, Université de Montpellier and CNRS, 34095 Montpellier, France
| |
Collapse
|
5
|
Durand A, Clua-Provost T, Fabre F, Kumar P, Li J, Edgar JH, Udvarhelyi P, Gali A, Marie X, Robert C, Gérard JM, Gil B, Cassabois G, Jacques V. Optically Active Spin Defects in Few-Layer Thick Hexagonal Boron Nitride. Phys Rev Lett 2023; 131:116902. [PMID: 37774304 DOI: 10.1103/physrevlett.131.116902] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/08/2023] [Accepted: 08/22/2023] [Indexed: 10/01/2023]
Abstract
Optically active spin defects in hexagonal boron nitride (hBN) are promising quantum systems for the design of two-dimensional quantum sensing units offering optimal proximity to the sample being probed. In this Letter, we first demonstrate that the electron spin resonance frequencies of boron vacancy centers (V_{B}^{-}) can be detected optically in the limit of few-atomic-layer thick hBN flakes despite the nanoscale proximity of the crystal surface that often leads to a degradation of the stability of solid-state spin defects. We then analyze the variations of the electronic spin properties of V_{B}^{-} centers with the hBN thickness with a focus on (i) the zero-field splitting parameters, (ii) the optically induced spin polarization rate and (iii) the longitudinal spin relaxation time. This Letter provides important insights into the properties of V_{B}^{-} centers embedded in ultrathin hBN flakes, which are valuable for future developments of foil-based quantum sensing technologies.
Collapse
Affiliation(s)
- A Durand
- Laboratoire Charles Coulomb, Université de Montpellier and CNRS, 34095 Montpellier, France
| | - T Clua-Provost
- Laboratoire Charles Coulomb, Université de Montpellier and CNRS, 34095 Montpellier, France
| | - F Fabre
- Laboratoire Charles Coulomb, Université de Montpellier and CNRS, 34095 Montpellier, France
| | - P Kumar
- Laboratoire Charles Coulomb, Université de Montpellier and CNRS, 34095 Montpellier, France
| | - J Li
- Tim Taylor Department of Chemical Engineering, Kansas State University, Kansas 66506, USA
| | - J H Edgar
- Tim Taylor Department of Chemical Engineering, Kansas State University, Kansas 66506, USA
| | - P Udvarhelyi
- Department of Atomic Physics, Budapest University of Technology and Economics, H-1111 Budapest, Hungary
| | - A Gali
- Department of Atomic Physics, Budapest University of Technology and Economics, H-1111 Budapest, Hungary
- Wigner Research Centre for Physics, P.O. Box 49, H-1525 Budapest, Hungary
| | - X Marie
- Université de Toulouse, INSA-CNRS-UPS, LPCNO, 135 Avenue Rangueil, 31077 Toulouse, France
| | - C Robert
- Université de Toulouse, INSA-CNRS-UPS, LPCNO, 135 Avenue Rangueil, 31077 Toulouse, France
| | - J M Gérard
- Univ. Grenoble Alpes, CEA, Grenoble INP, IRIG, PHELIQS, "Nanophysique et Semiconducteurs" Group, F-38000 Grenoble, France
| | - B Gil
- Laboratoire Charles Coulomb, Université de Montpellier and CNRS, 34095 Montpellier, France
| | - G Cassabois
- Laboratoire Charles Coulomb, Université de Montpellier and CNRS, 34095 Montpellier, France
| | - V Jacques
- Laboratoire Charles Coulomb, Université de Montpellier and CNRS, 34095 Montpellier, France
| |
Collapse
|
6
|
Ren L, Robert C, Glazov M, Semina M, Amand T, Lombez L, Lagarde D, Taniguchi T, Watanabe K, Marie X. Control of the Bright-Dark Exciton Splitting Using the Lamb Shift in a Two-Dimensional Semiconductor. Phys Rev Lett 2023; 131:116901. [PMID: 37774277 DOI: 10.1103/physrevlett.131.116901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/18/2023] [Accepted: 07/19/2023] [Indexed: 10/01/2023]
Abstract
We investigate the exciton fine structure in atomically thin WSe_{2}-based van der Waals heterostructures where the density of optical modes at the location of the semiconductor monolayer can be tuned. The energy splitting Δ between the bright and dark exciton is measured by photoluminescence spectroscopy. We demonstrate that Δ can be tuned by a few meV as a result of a significant Lamb shift of the optically active exciton that arises from emission and absorption of virtual photons triggered by the vacuum fluctuations of the electromagnetic field. We also measure strong variations of the bright exciton radiative linewidth as a result of the Purcell effect. All these experimental results illustrate the strong sensitivity of the excitons to local vacuum field fluctuations. We find a very good agreement with a model that demonstrates the equivalence, for our system, of a classical electrodynamical transfer matrix formalism and quantum-electrodynamical approach. The bright-dark splitting control we demonstrate here in the weak light-matter coupling regime should apply to any semiconductor structures.
Collapse
Affiliation(s)
- L Ren
- Université de Toulouse, INSA-CNRS-UPS, LPCNO, 135 Av. Rangueil, 31077 Toulouse, France
| | - C Robert
- Université de Toulouse, INSA-CNRS-UPS, LPCNO, 135 Av. Rangueil, 31077 Toulouse, France
| | - M Glazov
- Ioffe Institute, 26 Polytechnicheskaya, 194021 Saint Petersburg, Russia
| | - M Semina
- Ioffe Institute, 26 Polytechnicheskaya, 194021 Saint Petersburg, Russia
| | - T Amand
- Université de Toulouse, INSA-CNRS-UPS, LPCNO, 135 Av. Rangueil, 31077 Toulouse, France
| | - L Lombez
- Université de Toulouse, INSA-CNRS-UPS, LPCNO, 135 Av. Rangueil, 31077 Toulouse, France
| | - D Lagarde
- Université de Toulouse, INSA-CNRS-UPS, LPCNO, 135 Av. Rangueil, 31077 Toulouse, France
| | - T Taniguchi
- International Center for Materials Nanoarchitectonics, National Institute for Materials Science, 1-1 Namiki, Tsukuba 305-00044, Japan
| | - K Watanabe
- Research Center for Functional Materials, National Institute for Materials Science, 1-1 Namiki, Tsukuba 305-00044, Japan
| | - X Marie
- Université de Toulouse, INSA-CNRS-UPS, LPCNO, 135 Av. Rangueil, 31077 Toulouse, France
| |
Collapse
|
7
|
Febre M, Saulnier N, Roux P, Boutoille F, Girard N, Robert C, Rakic R, Rosset E, Maddens S. Placenta‐derived mesenchymal stromal cells as a treatment for refractory chronic gingivostomatitis in cats: eight cases (2018). J Small Anim Pract 2022; 64:296-305. [PMID: 36573276 DOI: 10.1111/jsap.13583] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2021] [Revised: 09/16/2022] [Accepted: 10/21/2022] [Indexed: 12/28/2022]
Abstract
OBJECTIVES The aim of this case series was to collect preliminary data on safety and efficacy of treating cats suffering from refractory feline chronic gingivostomatitis with a single intravenous therapy of cryopreserved placenta-derived mesenchymal stromal cells. MATERIALS AND METHODS We planned the prospective inclusion of cats suffering from refractory chronic gingivostomatitis in three veterinary clinics. All cats received a single infusion of 10×106 cryopreserved cells. Follow-up evaluations were done at day 15 and at 2-, 3- and 6-months following infusion. Clinical disease severity was evaluated by dental specialists using a published stomatitis disease activity index scoring system coupled with an owners' assessment questionnaire. RESULTS All eight cats attended all follow up visits. Cryopreserved ready-to-use placenta-derived cells administered systemically were safe and resulted in notable clinical improvement in all cats as reported by stomatitis disease activity index scoring and owner's survey. CLINICAL SIGNIFICANCE Infusion of cryopreserved freshly thawed placenta-derived mesenchymal stromal cells appears to promote clinical and consequently behavioural benefits in cats with refractory chronic gingivostomatitis after having undergone full-mouth or premolar-molar tooth extraction. Future randomised studies are required to confirm safety and efficacy of this treatment.
Collapse
Affiliation(s)
- M. Febre
- Vetbiobank SASMarcy‐l'ÉtoileFrance
| | | | - P. Roux
- DentovetLausanne, SuisseSwitzerland
| | | | | | | | - R. Rakic
- Vetbiobank SASMarcy‐l'ÉtoileFrance
| | - E. Rosset
- CHUVAC—VetAgro sup‐campus vétérinaireMarcy‐l'ÉtoileFrance
| | | |
Collapse
|
8
|
Luke J, Long G, Robert C, Carlino M, Choueiri T, Haas N, O'Brien M, Paz-Ares L, Peters S, Powles T, Leiby M, Lin J, Zhao Y, Krepler C, Perini R, Pietanza M, Samkari A, Gruber T, Ibrahim N, Eggermont A. 76P Safety profile of adjuvant pembrolizumab (pembro) in melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC): Pooled analysis of phase III clinical trials. Immuno-Oncology and Technology 2022. [DOI: 10.1016/j.iotech.2022.100180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
9
|
Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, Lyon AR, Wick W, Kostine M, Peters S, Jordan K, Larkin J. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33:1217-1238. [PMID: 36270461 DOI: 10.1016/j.annonc.2022.10.001] [Citation(s) in RCA: 170] [Impact Index Per Article: 85.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2022] [Revised: 09/30/2022] [Accepted: 10/02/2022] [Indexed: 11/17/2022] Open
Affiliation(s)
- J Haanen
- Division of Medical Oncology, Netherlands Cancer Institute (NKI), Amsterdam, The Netherlands
| | - M Obeid
- Immunology and Allergy Service, CHUV, Lausanne; Lausanne Center for Immuno-oncology Toxicities (LCIT), CHUV, Lausanne; Department of Oncology, CHUV, Lausanne, Switzerland
| | - L Spain
- Medical Oncology Department, Peter MacCallum Cancer Centre, Melbourne; Department of Medical Oncology, Eastern Health, Melbourne; Monash University Eastern Health Clinical School, Box Hill, Australia
| | - F Carbonnel
- Gastroenterology Department, Assistance Publique-Hôpitaux de Paris, Hôpital Universitaire Bicêtre, Le Kremlin Bicêtre, France; Université Paris Saclay 11, Le Kremlin-Bicêtre, France
| | - Y Wang
- Department of Gastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - C Robert
- Department of Medicine, Gustave Roussy Cancer Centre, Villejuif; Paris-Saclay University, Villejuif, France
| | - A R Lyon
- Cardio-Oncology Service, Royal Brompton Hospital, London; National Heart and Lung Institute, Imperial College London, London, UK
| | - W Wick
- Neurology Clinic and National Centre for Tumour Diseases, University Hospital Heidelberg, Heidelberg; DKTK and Clinical Cooperation Unit NeuroOncology, DKFZ, Heidelberg, Germany
| | - M Kostine
- Department of Rheumatology, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France
| | - S Peters
- Department of Oncology, CHUV, Lausanne, Switzerland
| | - K Jordan
- Department of Haematology, Oncology and Palliative Medicine, Ernst von Bergmann Hospital Potsdam, Potsdam; Department of Haematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
| | - J Larkin
- Royal Marsden NHS Foundation Trust, London, UK
| |
Collapse
|
10
|
Lebbe C, Long G, Robert C, Hamid O, Atkinson V, Shoushtari A, Daud A, Bechter O, Schadendorf D, Sullivan R, Dummer R, Grob J, Lewis N, Fan L, Basu S, Caponigro G, Cooke V, Lau A, Amaria R. LBA40 Phase II study of multiple LXH254 drug combinations in patients (pts) with unresectable/metastatic, BRAF V600- or NRAS-mutant melanoma. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.08.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
11
|
Dummer R, Pathan N, Deng S, Robert C, Arance Fernandez A, de Groot J, Garbe C, Gogas H, Gutzmer R, Krajsova I, Liszkay G, Loquai C, Mandala M, Schadendorf D, Yamazaki N, di Pietro A, Xie T, Ascierto P, Flaherty K. 786O Tumor biomarker analysis from COLUMBUS part 1: Encorafenib + binimetinib for BRAF V600E/K-mutant advanced or metastatic melanoma. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.912] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
12
|
Nathan P, Grob J, Dummer R, Ascierto P, Ribas A, Robert C, Schadendorf D, Flaherty K, Tawbi H, Hauschild A, Mandala M, Shah R, Banerjee H, Sarkar R, Lau M, Long G. 819P Efficacy of dabrafenib (D) trametinib (T) plus spartalizumab (S) by baseline site of metastases in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Post hoc analysis of phase III COMBI-i trial. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.945] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
13
|
Robert C, Migden M, Day F, Bowyer S, Hofheinz R, Chrom P, Heeger S, Rischin D. 885TiP The I-PACE study: Imgatuzumab in PAtients with advanCEd cutaneous squamous cell carcinoma (aCSCC). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
14
|
Lewis K, Robert C, Ramella Munhoz R, Liszkay G, de la Cruz Merino L, Olah J, Queirolo P, Mackiewicz J, Li H, Zhu Q, Hertig C, Paranthaman N, McKenna E, Gutzmer R, McArthur G, Ascierto P. 813P Time to development of central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined with vemurafenib (V) + cobimetinib (C): Updated results from the phase III IMspire150 study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.939] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
15
|
Del Vecchio M, Atkinson V, Ryll B, Menzies A, Aubin F, Chiarion Sileni V, Ferraresi V, Lesimple T, Rinaldi G, Saiag P, Robert C, Dutriaux C, Gogas H, Demidov L, Gupta A, Banerjee H, Sudhir S, Miranda F, Lau M, Grob J. 806P Updated toxicity profile and relapse-free survival outcomes using an adapted pyrexia management algorithm in patients with resected stage III BRAF V600E/K-mutant melanoma treated with adjuvant dabrafenib plus trametinib in COMBI-APlus. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.932] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
16
|
Eggermont A, Kicinski M, Blank C, Mandala M, Long G, Atkinson V, Dalle S, Haydon A, Meshcheryakov A, Khattak A, Carlino M, Sandhu S, Puig Sarda S, Ascierto P, Lorigan P, Grebennik D, Ibrahim N, Marreaud S, Suciu S, Robert C. 804P Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.930] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
17
|
Bottomley A, Kicinski M, Long G, Mandala M, Atkinson V, Blank C, Haydon A, Dalle S, Khattak A, Carlino M, Meshcheryakov A, Sandhu S, Sarda SP, Coens C, Suciu S, Grebennik D, Krepler C, Lorigan P, Robert C, Eggermont A. LBA44 Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Long-term quality of life analysis results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.08.043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
18
|
Ren L, Lombez L, Robert C, Beret D, Lagarde D, Urbaszek B, Renucci P, Taniguchi T, Watanabe K, Crooker SA, Marie X. Optical Detection of Long Electron Spin Transport Lengths in a Monolayer Semiconductor. Phys Rev Lett 2022; 129:027402. [PMID: 35867459 DOI: 10.1103/physrevlett.129.027402] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/27/2022] [Accepted: 05/18/2022] [Indexed: 06/15/2023]
Abstract
Using a spatially resolved optical pump-probe experiment, we measure the lateral transport of spin-valley polarized electrons over very long distances (tens of micrometers) in a single WSe_{2} monolayer. By locally pumping the Fermi sea of 2D electrons to a high degree of spin-valley polarization (up to 75%) using circularly polarized light, the lateral diffusion of the electron polarization can be mapped out via the photoluminescence induced by a spatially separated and linearly polarized probe laser. Up to 25% spin-valley polarization is observed at pump-probe separations up to 20 μm. Characteristic spin-valley diffusion lengths of 18±3 μm are revealed at low temperatures. The dependence on temperature, pump helicity, pump intensity, and electron density highlight the key roles played by spin relaxation time and pumping efficiency on polarized electron transport in monolayer semiconductors possessing spin-valley locking.
Collapse
Affiliation(s)
- L Ren
- Université de Toulouse, INSA-CNRS-UPS, LPCNO, 135 Av. Rangueil, 31077 Toulouse, France
| | - L Lombez
- Université de Toulouse, INSA-CNRS-UPS, LPCNO, 135 Av. Rangueil, 31077 Toulouse, France
| | - C Robert
- Université de Toulouse, INSA-CNRS-UPS, LPCNO, 135 Av. Rangueil, 31077 Toulouse, France
| | - D Beret
- Université de Toulouse, INSA-CNRS-UPS, LPCNO, 135 Av. Rangueil, 31077 Toulouse, France
| | - D Lagarde
- Université de Toulouse, INSA-CNRS-UPS, LPCNO, 135 Av. Rangueil, 31077 Toulouse, France
| | - B Urbaszek
- Université de Toulouse, INSA-CNRS-UPS, LPCNO, 135 Av. Rangueil, 31077 Toulouse, France
| | - P Renucci
- Université de Toulouse, INSA-CNRS-UPS, LPCNO, 135 Av. Rangueil, 31077 Toulouse, France
| | - T Taniguchi
- International Center for Materials Nanoarchitectonics, National Institute for Materials Science, 1-1 Namiki, Tsukuba 305-00044, Japan
| | - K Watanabe
- Research Center for Functional Materials, National Institute for Materials Science, 1-1 Namiki, Tsukuba 305-00044, Japan
| | - S A Crooker
- National High Magnetic Field Laboratory, Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - X Marie
- Université de Toulouse, INSA-CNRS-UPS, LPCNO, 135 Av. Rangueil, 31077 Toulouse, France
| |
Collapse
|
19
|
Dimitriou F, Namikawa K, Reijers ILM, Buchbinder EI, Soon JA, Zaremba A, Teterycz P, Mooradian MJ, Armstrong E, Nakamura Y, Vitale MG, Tran LE, Bai X, Allayous C, Provent-Roy S, Indini A, Bhave P, Farid M, Kähler KC, Mehmi I, Atkinson V, Klein O, Stonesifer CJ, Zaman F, Haydon A, Carvajal RD, Hamid O, Dummer R, Hauschild A, Carlino MS, Mandala M, Robert C, Lebbe C, Guo J, Johnson DB, Ascierto PA, Shoushtari AN, Sullivan RJ, Cybulska-Stopa B, Rutkowski P, Zimmer L, Sandhu S, Blank CU, Lo SN, Menzies AM, Long GV. Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. Ann Oncol 2022; 33:968-980. [PMID: 35716907 DOI: 10.1016/j.annonc.2022.06.004] [Citation(s) in RCA: 18] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2022] [Revised: 05/15/2022] [Accepted: 06/07/2022] [Indexed: 11/01/2022] Open
Abstract
BACKGROUND Mucosal melanoma (MM) is a rare melanoma subtype with distinct biology and poor prognosis. Data on the efficacy of immune checkpoint inhibitors (ICIs) is limited. We determined the efficacy of ICIs in MM, analysed by primary site and ethnicity/race. PATIENTS AND METHODS Retrospective cohort study from 25 cancer centres in Australia, Europe, USA and Asia. Patients with histologically confirmed MM were treated with anti-PD1+/-ipilimumab. Primary endpoints were response rate (RR), progression-free survival (PFS), overall survival (OS) by primary site (naso-oral, urogenital, anorectal, other), ethnicity/race (Caucasian, Asian, Other) and treatment. Univariate and multivariate Cox proportional hazard model analyses were conducted. RESULTS In total, 545 patients were included: 331 (63%) Caucasian, 176 (33%) Asian and 20 (4%) Other. Primary sites included 113 (21%) anorectal, 178 (32%) urogenital, 206 (38%) naso-oral and 45 (8%) other. 348 (64%) received anti-PD1 and 197 (36%) anti-PD1/ipilimumab. RR, PFS and OS did not differ by primary site, ethnicity/race or treatment. RR for naso-oral was numerically higher for anti-PD1/ipilimumab (40%, 95% CI 29-54%) compared with anti-PD1 (29%, 95% CI 21-37%). 35% of patients that initially responded progressed. Median duration of response (mDOR) was 26 months (95% CI 18-NR [Not Reached]). Factors associated with short PFS were ECOG PS ≥3 (p<0.01), LDH >ULN (p=0.01), lung metastases (p<0.01) and ≥1 previous treatments (p<0.01). Factors associated with short OS were ECOG PS ≥1 (p<0.01), LDH >ULN (p=0.03), lung metastases (p<0.01) and ≥1 previous treatments (p<0.01). CONCLUSIONS MM has poor prognosis. Treatment efficacy of anti-PD1+/-ipilimumab was similar and did not differ by ethnicity/race. Naso-oral primaries had numerically higher response to anti-PD1/ipilimumab, without difference in survival. The addition of ipilimumab did not show greater benefit over anti-PD1 for other primary sites. In responders, mDOR was short and acquired resistance was common. Other factors, including site and number of metastases were associated with survival.
Collapse
Affiliation(s)
- F Dimitriou
- Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia; Department of Dermatology, University Hospital Zurich (USZ) and University of Zurich (UZH), Zurich, Switzerland; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
| | - K Namikawa
- Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - I L M Reijers
- Department of Medical Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - E I Buchbinder
- Melanoma Disease Center, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02481, USA
| | - J A Soon
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - A Zaremba
- Department of Dermatology, University Hospital Essen, Essen, Germany
| | - P Teterycz
- Department of Soft Tissue/Bone Sarcoma and Melanoma, 49585Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
| | - M J Mooradian
- Division of Oncology and Hematology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston MA, USA
| | - E Armstrong
- Department of Medicine, Melanoma Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Y Nakamura
- Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center, Saitama, Japan
| | - M G Vitale
- Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale', Napoli, Italy
| | - L E Tran
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | - X Bai
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute, Beijing, China
| | - C Allayous
- APHP Hôpital Saint-Louis, Dermatology Department, DMU ICARE, Paris, France
| | - S Provent-Roy
- Dermatology Service, Department of Medicine, Gustave Roussy and Paris-Saclay University, Villejuif, France
| | - A Indini
- Unit of Medical Oncology, Ospedale di Circolo e Fondazione Macchi, ASST Sette Laghi, Varese, Italy
| | - P Bhave
- Westmead and Blacktown Hospitals, Sydney, New South Wales, Australia
| | - M Farid
- Division of Medical Oncology, National Cancer Centre Singapore, 11 Hospital Crescent, Singapore, 169610, Singapore
| | - K C Kähler
- Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, Germany
| | - I Mehmi
- Department of Hematology/Oncology, The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, 11800 Wilshire Blvd Suite 300, Los Angeles, CA, 90025, USA
| | - V Atkinson
- Princess Alexandra Hospital, Greenslopes Private Hospital, University of Queensland, Queensland, Australia
| | - O Klein
- Department of Medical Oncology, Austin Health, Melbourne, Australia; Olivia Newton-John Cancer Research Institute, Melbourne, Victoria
| | - C J Stonesifer
- Columbia University Irving Medical Center, New York City, New York, USA
| | - F Zaman
- Alfred Hospital, Melbourne, Victoria, Australia
| | - A Haydon
- Alfred Hospital, Melbourne, Victoria, Australia
| | - R D Carvajal
- Columbia University Irving Medical Center, New York City, New York, USA
| | - O Hamid
- Department of Hematology/Oncology, The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, 11800 Wilshire Blvd Suite 300, Los Angeles, CA, 90025, USA
| | - R Dummer
- Department of Dermatology, University Hospital Zurich (USZ) and University of Zurich (UZH), Zurich, Switzerland
| | - A Hauschild
- Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, Germany
| | - M S Carlino
- Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia; Westmead and Blacktown Hospitals, Sydney, New South Wales, Australia
| | - M Mandala
- Unit of Medical Oncology, University of Perugia, Perugia, Italy
| | - C Robert
- Dermatology Service, Department of Medicine, Gustave Roussy and Paris-Saclay University, Villejuif, France
| | - C Lebbe
- Université de Paris, APHP Hôpital Saint-Louis, Dermatology Department, DMU ICARE, INSERM U-976, Paris, France
| | - J Guo
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute, Beijing, China
| | - D B Johnson
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | - P A Ascierto
- Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale', Napoli, Italy
| | - A N Shoushtari
- Department of Medicine, Melanoma Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - R J Sullivan
- Division of Oncology and Hematology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston MA, USA
| | - B Cybulska-Stopa
- Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Cracow Branch, Poland
| | - P Rutkowski
- Department of Soft Tissue/Bone Sarcoma and Melanoma, 49585Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
| | - L Zimmer
- Department of Dermatology, University Hospital Essen, Essen, Germany
| | - S Sandhu
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - C U Blank
- Department of Medical Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - S N Lo
- Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
| | - A M Menzies
- Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia
| | - G V Long
- Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia.
| |
Collapse
|
20
|
Alvarez Andres E, Gasnier A, Veres C, Dhermain F, Corbin S, Auville F, Biron B, Vatonne A, Henry T, Estienne T, Lerousseau M, Carré A, Fidon L, Deutsch E, Paragios N, Robert C. PO-1623 Characterisation of synthetic CTs clinical quality: which gamma indices to evaluate in practice? Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03587-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
21
|
de Kermenguy F, Alvarez Andres E, De Marzi L, Fidon L, Carré A, Bolle S, Paragios N, Deutsch E, Ammari S, Robert C. PO-1621 An efficient training approach for brain paediatrics synthetic CT generation for protontherapy. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03585-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
22
|
Bondiau P, Bolle S, Escande A, Duverge L, Demoor C, Rouyar-Nicolas A, Bertrand B, Cannard A, Hardy L, Martineau-Huynh C, Paragios N, Roque T, Deutsch E, Robert C. PD-0330 AI-based OAR annotation for pediatric brain radiotherapy planning. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02823-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
23
|
Volod O, Lam L, Robert C, Moriguchi J, Yur J, Garcia M, Zhou J, Wilde A, Czer L. Determining Cause for Activated Partial Thromboplastin Time and Anti-Factor Xa Discordance in Mechanical Circulatory Support Patients on Heparin; Can Thromboelastogram Help? J Heart Lung Transplant 2022. [DOI: 10.1016/j.healun.2022.01.1170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
24
|
Basin S, Valentin S, Maurac A, Pequignot B, Brindel A, Robert C, Baumann C, Luc A, Poussel M, Chabot F, Chaouat A. Évaluation de la prévalence des formes critiques de la COVID-19 parmi les patients hospitalisés porteurs d’une maladie respiratoire chronique. Revue des Maladies Respiratoires Actualités 2022. [PMCID: PMC8709704 DOI: 10.1016/j.rmra.2021.11.136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Introduction Les infections virales respiratoires, dont l’infection à SARS-CoV-2, peuvent déclencher des symptômes respiratoires chez les patients souffrant de maladies respiratoires chroniques, entraînant des exacerbations et parfois des hospitalisations. Malgré le tropisme préférentiellement respiratoire du SARS-CoV-2, les études évaluant les maladies respiratoires chroniques comme facteurs de risque de forme critique de la COVID-19 sont controversées. L’objectif de cette étude était d’évaluer la prévalence de formes critiques de la COVID-19 chez les patients hospitalisés porteurs d’une maladie respiratoire chronique. Méthodes Cette étude rétrospective française bicentrique a inclus tous les patients hospitalisés du 15 mars au 30 juin 2020 pour motif respiratoire liée à la COVID-19, hors unités de soins intensifs et réanimation. Résultats Au total, 617 patients ont été inclus dont 125 présentant une maladie respiratoire chronique, principalement une bronchopneumopathie chronique obstructive (45 %) et un asthme (30 %) (Tableau 1). Le pourcentage de patients ayant obtenu un score de 6 ou plus sur l’échelle de progression clinique de l’Organisation mondiale de la santé 1 pendant leur hospitalisation était plus faible chez les patients atteints d’une maladie respiratoire chronique que dans la population générale (21,6 % contre 31,3 %, p = 0,03 %). Parmi les patients porteurs d’une maladie respiratoire chronique, une température supérieure à 38 °C à l’admission (OR 16,88 [IC 95 % 4,01–71,00]), une lymphopénie (OR 5,08 [1,25–20,72]), un traitement par pression positive continue (OR 4,46 [1,04–19,17]) et un âge élevé (OR 1,09 [1,02–1,16]) étaient associés à un risque accru d’atteindre un score de 6 ou plus. Conclusion Selon cette étude, les patients porteurs d’une maladie respiratoire chronique hospitalisés pour forme grave de la COVID-19 ont un risque plus faible de développer une forme critique de la maladie, en particulier les patients souffrant d’une broncho-pneumopathie chronique obstructive et d’un asthme. Des études prospectives pourraient permettre de confirmer nos résultats et d’éclaircir l’impact des traitements inhalés et notamment de la corticothérapie sur la sévérité des infections à SARS-CoV-2.
Collapse
|
25
|
Abstract
Gliomas are the most frequent primary brain tumour. The proximity of organs at risk, the infiltrating nature, and the radioresistance of gliomas have to be taken into account in the choice of prescribed dose and technique of radiotherapy. The management of glioma patients is based on clinical factors (age, KPS) and tumour characteristics (histology, molecular biology, tumour location), and strongly depends on available and associated treatments, such as surgery, radiation therapy, and chemotherapy. The knowledge of molecular biomarkers is currently essential, they are increasingly evolving as additional factors that facilitate diagnostics and therapeutic decision-making. We present the update of the recommendations of the French society for radiation oncology on the indications and the technical procedures for performing radiation therapy in patients with gliomas.
Collapse
Affiliation(s)
- D Antoni
- Service de radiothérapie, institut cancérologie Strasbourg Europe (ICANS), 17, rue Albert-Calmette, 67200 Strasbourg cedex, France.
| | - L Feuvret
- Service de radiothérapie, CHU Pitié-Salpêtrière, Assistance publique-hôpitaux de Paris (AP-HP), 47-83, boulevard de l'Hôpital, 75013 Paris, France
| | - J Biau
- Département universitaire de radiothérapie, centre Jean-Perrin, Unicancer, 58, rue Montalembert, BP 392, 63011 Clermont-Ferrand cedex 01, France
| | - C Robert
- Département de radiothérapie, institut de cancérologie Gustave-Roussy, 39, rue Camille-Desmoulin, 94800 Villejuif, France
| | - J-J Mazeron
- Service de radiothérapie, CHU Pitié-Salpêtrière, Assistance publique-hôpitaux de Paris (AP-HP), 47-83, boulevard de l'Hôpital, 75013 Paris, France
| | - G Noël
- Service de radiothérapie, institut cancérologie Strasbourg Europe (ICANS), 17, rue Albert-Calmette, 67200 Strasbourg cedex, France
| |
Collapse
|
26
|
Miao Y, Kolb F, Tomasic G, Lupu J, Routier E, Robert C. Keratoacanthoma or cutaneous squamous cell carcinoma revealing a DNA mismatch repair default (Muir-Torre Syndrome). J Eur Acad Dermatol Venereol 2021; 36 Suppl 1:74-76. [PMID: 34855250 DOI: 10.1111/jdv.17399] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2021] [Accepted: 05/19/2021] [Indexed: 11/30/2022]
Abstract
Keratoacanthoma (KA) and well-differentiated cutaneous squamous cell carcinoma (cSCC) are hardly distinguishable clinically and histologically. They both can be seen in patients with hereditary non-polyposis colorectal cancer (HNPCC) or Lynch Syndrome, corresponding to DNA microsatellite instability. In our case, a young man had the excision of two rapidly growing skin tumours for which distinction between KA and cSCC was initially clinically and pathologically challenging. The diagnosis of well-differentiated cSCCs was made and the patient was treated with surgery. Ten years after the first cSCC, he was diagnosed with Muir-Torre syndrome, a variant of Lynch syndrome, with an heterozygote mutation of the MSH2 gene. This later diagnosis allowed to screen his family members for the same mutation and to adopt an appropriate follow-up regarding the risk of digestive tumours for him and his family. Furthermore, it is important to know that, in case of non-resectable cSCC occurring in this patient, immunotherapy using anti-PD1 antibody would probably be effective due to the known increased immunogenicity of MMR deficient tumours.
Collapse
Affiliation(s)
- Y Miao
- Dermatology Service, Department of Medicine, Gustave Roussy, Villejuif, France
| | - F Kolb
- Plastic Surgery Service, Department of Surgery, Gustave Roussy, Villejuif, France
| | - G Tomasic
- Department of Pathology, Gustave Roussy, Villejuif, France
| | - J Lupu
- Dermatology Service, Department of Medicine, Gustave Roussy, Villejuif, France
| | - E Routier
- Dermatology Service, Department of Medicine, Gustave Roussy, Villejuif, France
| | - C Robert
- Dermatology Service, Department of Medicine, Gustave Roussy, Villejuif, France.,Paris Saclay University, Orsay, France
| |
Collapse
|
27
|
Camblats AM, Robert C, Mathey S. Le voisinage orthographique influence la catégorisation de couleur des mots différemment selon l’âge et la vitesse de traitement. Psychologie Française 2021. [DOI: 10.1016/j.psfr.2021.10.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
28
|
Sauvage C, Robert C, Mugnier LM, Conan JM, Cohard JM, Nguyen KL, Irvine M, Lagouarde JP. Near ground horizontal high resolution Cn2 profiling from Shack-Hartmann slopeand scintillation data. Appl Opt 2021; 60:10499-10519. [PMID: 35200911 DOI: 10.1364/ao.438170] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/26/2021] [Accepted: 10/30/2021] [Indexed: 06/14/2023]
Abstract
Coupled slope and scintillation detection and ranging (CO-SLIDAR) is a very promising technique for the metrology of near ground Cn2 profiles. It exploits both phase and scintillation measurements obtained with a dedicated wavefront sensor and allows profiling on the full line of sight between pupil and sources. This technique is applied to an associated instrument based on a mid-IR Shack-Hartmann wavefront sensor coupled to a 0.35 m telescope, which observes two cooperative sources. This paper presents what we believe is the first comprehensive description of the CO-SLIDAR method in the context of near-ground optical turbulence metrology. It includes the presentation of the physics principles underlying the measurements of our unsupervised Cn2 profile reconstruction strategy together with the error bar estimation on the reconstructed values. The application to data acquired in a heterogeneous rural landscape during an experimental campaign in Lannemezan, France, demonstrates the ability to obtain profiles with a sampling pitch of about 220 m over a 2.7 km line of sight. The retrieved Cn2 profiles are presented and their variability in space and time is discussed.
Collapse
|
29
|
Long GV, Arance A, Mortier L, Lorigan P, Blank C, Mohr P, Schachter J, Grob JJ, Lotem M, Middleton MR, Neyns B, Steven N, Ribas A, Walpole E, Carlino MS, Lebbe C, Sznol M, Jensen E, Leiby MA, Ibrahim N, Robert C. Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006. Ann Oncol 2021; 33:204-215. [PMID: 34710571 DOI: 10.1016/j.annonc.2021.10.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2021] [Revised: 10/13/2021] [Accepted: 10/14/2021] [Indexed: 11/17/2022] Open
Abstract
BACKGROUND Antitumor activity of ipilimumab or BRAF ± MEK inhibitors (BRAFi ± MEKi) following pembrolizumab administration in melanoma is poorly characterized. PATIENTS AND METHODS In the phase III KEYNOTE-006 study, patients with unresectable stage III/IV melanoma received pembrolizumab (10 mg/kg) once every 2 or 3 weeks (Q3W) or ipilimumab (3 mg/kg) Q3W. The current post hoc analysis evaluates outcomes with ipilimumab or BRAFi ± MEKi as first subsequent systemic therapy after pembrolizumab administration and includes patients who completed or discontinued pembrolizumab after one or more dose. Pembrolizumab arms were pooled. RESULTS At data cut-off (4 December 2017), median follow-up was 46.9 months. Of 555 pembrolizumab-treated patients, first subsequent therapy was ipilimumab for 103 (18.6%) and BRAFi ± MEKi for 59 (10.6%) [33 received BRAFi + MEKi, 26 BRAFi alone; 37 (62.7%) were BRAFi ± MEKi naïve]. In the subsequent ipilimumab group, ORR with previous pembrolizumab was 17.5% [1 complete response (CR); 17 partial response (PR)]; 79.6% had discontinued pembrolizumab due to progressive disease (PD); median overall survival (OS) was 21.5 months. ORR with subsequent ipilimumab was 15.5%; 11/16 responses (8 CRs; 3 PRs) were ongoing. ORR with subsequent ipilimumab was 9.7% for patients with PD as best response to pembrolizumab. Median OS from ipilimumab initiation was 9.8 months. In the subsequent BRAFi ± MEKi group, ORR with previous pembrolizumab was 13.5% (8 PR); 76.3% had discontinued pembrolizumab due to PD; median OS was 17.9 months. ORR with subsequent BRAFi ± MEKi was 30.5%, 7/18 responses (4 CR, 3 PR) were ongoing. Median OS from BRAFi ± MEKi initiation was 12.9 months. ORR for BRAFi ± MEKi-naïve patients who received subsequent BRAFi ± MEKi was 43.2%; 6/16 were ongoing (3 CR, 3 PR). CONCLUSIONS Ipilimumab and BRAFi ± MEKi have antitumor activity as first subsequent therapy after pembrolizumab in patients with advanced melanoma.
Collapse
Affiliation(s)
- G V Long
- Melanoma Institute Australia, The University of Sydney, Mater Hospital, Sydney, Australia; Faculty of Medicine & Health, The University of Sydney, Sydney, Australia; Charles Perkins Centre, The University of Sydney, Sydney, Australia; Royal North Shore Hospital, Sydney, Australia.
| | - A Arance
- Hospital Clinic de Barcelona, Barcelona, Spain
| | - L Mortier
- Université Lille, Centre Hospitalier Régional Universitaire de Lille, Lille, France
| | - P Lorigan
- Division of Cancer Sciences, University of Manchester, Manchester; Christie NHS Foundation Trust, Manchester, UK
| | - C Blank
- Netherlands Cancer Institute, Amsterdam, Netherlands
| | - P Mohr
- Elbe-Klinikum Buxtehude, Buxtehude, Germany
| | - J Schachter
- Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center at Tel Hashomer, Ramat Gan, Israel
| | - J-J Grob
- Aix Marseille University, Hôpital de la Timone, Marseille, France
| | - M Lotem
- Sharett Institute of Oncology, Hadassah Hebrew Medical Center, Jerusalem, Israel
| | - M R Middleton
- The Churchill Hospital and The University of Oxford, Oxford, UK
| | - B Neyns
- Universitair Ziekenhuis Brussel, Brussels, Belgium
| | - N Steven
- Queen Elizabeth Hospital, Birmingham, UK
| | - A Ribas
- David Geffen School of Medicine, University of California, Los Angeles, USA
| | - E Walpole
- Princess Alexandra Hospital, Brisbane, Australia; University of Queensland, Brisbane, Australia
| | - M S Carlino
- Melanoma Institute Australia, The University of Sydney, Mater Hospital, Sydney, Australia; Westmead and Blacktown Hospitals, Melanoma Institute Australia, Sydney, Australia; University of Sydney, Sydney, Australia
| | - C Lebbe
- Université de Paris, AP-HP Dermatology and CIC, INSERM U976, Saint Louis Hospital, Paris, France
| | - M Sznol
- Yale Cancer Center, New Haven, USA
| | - E Jensen
- Merck & Co., Inc., Kenilworth, USA
| | | | | | - C Robert
- Department of Oncology, Service of Dermatology, Gustave Roussy, Villejuif, France; Paris-Saclay University, Orsay, France
| |
Collapse
|
30
|
Dummer R, Flaherty K, Robert C, Arance A, de Groot J, Garbe C, Gogas H, Gutzmer R, Krajsová I, Liszkay G, Loquai C, Mandala M, Schadendorf D, Yamazaki N, Zohren F, Edwards M, Ascierto P. 1041MO 5-year update on COLUMBUS: A randomized phase III trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1426] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
31
|
Schadendorf D, Dummer R, Robert C, Ribas A, Sullivan R, Panella T, Mckean M, Santos E, Brill K, Polli A, di Pietro A, Ascierto P. 1091TiP STARBOARD: Randomized phase III study of encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of metastatic or unresectable locally advanced BRAF V600-mutant melanoma. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1476] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
32
|
Robert C, Schadendorf D, Long G, Ascierto P, Intagliata S, Meier F, van der Veldt A, Ribas A, Weber J, Stenson L, Solovieff N, Louveau AL, Boran A, Grob J, Dummer R. 1084P PLATForM: Descriptive analysis from a randomised, phase II study of novel spartalizumab combinations in previously treated unresectable/metastatic melanoma. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1469] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
33
|
Bhave P, Ahmed T, Shoushtari A, Zaremba A, Versluis J, Mangana J, Weichenthal M, Si L, Lesimple T, Robert C, Trojaniello C, Wicky A, Heywood R, Tran L, Batty K, Stansfeld A, Lebbe C, Schwarze J, Mooradian M, Carlino M. 1047P Efficacy of checkpoint inhibitors (CPIs) in acral melanoma (AM). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1432] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
34
|
Danlos FX, Goubet AG, Aglave M, Alfaro A, Job B, Francillette M, Hanna A, Pradere P, Dolidon S, Lecluse Y, Droin N, Deloger M, Besse B, Robert C, Michot JM, Soria JC, Barlesi F, Zitvogel L, Marabelle A, Le Pavec J. 1773P Anti-PD1-induced acute interstitial pneumonitis is characterized by alveolar infiltration of PD-1+CD38+TIGIT+ cytotoxic effector CD8+ T cells and CD206+ inflammatory macrophages. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1717] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
35
|
Dimitriou F, Namikawa K, Teterycz P, Reijers I, Buchbinder E, Soon J, Zimmer L, Mooradian M, Vitale M, Armstrong E, Johnson D, Guo J, Lebbe C, Robert C, Mandala M, Bhave P, Farid M, Kähler K, Lo S, Long G. 1049P Clinical models to predict response in mucosal melanoma (MM) patients (pts) treated with anti-PD-1 (PD1) or combined with ipilimumab (PD1+IPI). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1434] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
36
|
Robert C, Davies M, Dummer R, Grob J, Hauschild A, Kirkwood J, Long G, Mandalà M, Nathan P, Banerjee H, Sahoo B, Lau M, Biette K, Boran A, Schadendorf D. 1075P Regression tree analysis to identify factors associated with relapse-free survival (RFS) in patients with resected stage III BRAF V600E/K–mutant melanoma. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1460] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
37
|
Grob J, Aubin F, Benmahammed-Bellagha L, Brunet-Possenti F, Dereure O, Dutriaux C, Duval-Modeste AB, Grange F, Jarvis C, Kramkimel N, Leccia MT, Machet L, Meyer N, Mortier L, Neidhardt EM, Robert C, Scherrer E, Spampinato A, Verdoni L, Saiag P. 1080P HORIZON: Final results from a 5-year ambispective study of 705 patients who initiated pembrolizumab for advanced melanoma in the French early access program. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1465] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
38
|
Loriot Y, Marabelle A, Guégan JP, Danlos FX, Besse B, Chaput N, Massard C, Planchard D, Robert C, Even C, Khettab M, Tselikas L, Friboulet L, André F, Nafia I, Le Loarer F, Soria JC, Bessede A, Italiano A. Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance. Ann Oncol 2021; 32:1381-1390. [PMID: 34416362 DOI: 10.1016/j.annonc.2021.08.1748] [Citation(s) in RCA: 26] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2021] [Revised: 07/23/2021] [Accepted: 08/06/2021] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND Immune checkpoint blockers (ICBs) are now widely used in oncology. Most patients, however, do not derive benefit from these agents. Therefore, there is a crucial need to identify novel and reliable biomarkers of resistance to such treatments in order to prescribe potentially toxic and costly treatments only to patients with expected therapeutic benefits. In the wake of genomics, the study of proteins is now emerging as the new frontier for understanding real-time human biology. PATIENTS AND METHODS We analyzed the proteome of plasma samples, collected before treatment onset, from two independent prospective cohorts of cancer patients treated with ICB (discovery cohort n = 95, validation cohort n = 292). We then investigated the correlation between protein plasma levels, clinical benefit rate, progression-free survival and overall survival by Cox proportional hazards models. RESULTS By using an unbiased proteomics approach, we show that, in both discovery and validation cohorts, elevated baseline serum level of leukemia inhibitory factor (LIF) is associated with a poor clinical outcome in cancer patients treated with ICB, independently of other prognostic factors. We also demonstrated that the circulating level of LIF is inversely correlated with the presence of tertiary lymphoid structures in the tumor microenvironment. CONCLUSION This novel clinical dataset brings strong evidence for the role of LIF as a potential suppressor of antitumor immunity and suggests that targeting LIF or its pathway may represent a promising approach to improve efficacy of cancer immunotherapy in combination with ICB.
Collapse
Affiliation(s)
- Y Loriot
- Cancer Medicine Department, INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - A Marabelle
- Département d'Innovation Précoce et d'Essais Thérapeutiques (DITEP), INSERM U1015 & CIC1428, Université Paris Saclay, Gustave Roussy, Villejuif, France
| | | | - F X Danlos
- Département d'Innovation Précoce et d'Essais Thérapeutiques (DITEP), INSERM U1015 & CIC1428, Université Paris Saclay, Gustave Roussy, Villejuif, France
| | - B Besse
- Cancer Medicine Department, INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, France; Faculty of Medicine, University Paris-Saclay, Le Kremlin Bicêtre, France
| | - N Chaput
- Laboratory of Immunomonitoring in Oncology, Gustave Roussy Cancer Campus, CNRS-UMS 3655 and INSERM-US23, Villejuif, France; Faculty of Pharmacy, University Paris-Saclay, Chatenay-Malabry, France; Laboratory of Genetic Instability and Oncogenesis, UMR CNRS 8200, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - C Massard
- Département d'Innovation Précoce et d'Essais Thérapeutiques (DITEP), INSERM U1015 & CIC1428, Université Paris Saclay, Gustave Roussy, Villejuif, France
| | - D Planchard
- Cancer Medicine Department, INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - C Robert
- Cancer Medicine Department, INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - C Even
- Cancer Medicine Department, INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - M Khettab
- Cancer Medicine Department, INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - L Tselikas
- Interventional Radiology, Gustave Roussy, Villejuif, France
| | - L Friboulet
- Université Paris-Saclay, Institut Gustave Roussy, Inserm U981, Biomarqueurs prédictifs et nouvelles stratégies thérapeutiques en oncologie, Villejuif, France
| | - F André
- Cancer Medicine Department, INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, France; Faculty of Medicine, University Paris-Saclay, Le Kremlin Bicêtre, France
| | | | - F Le Loarer
- Department of Pathology, Institut Bergonié, Bordeaux, France; Faculty of Medicine, University of Bordeaux, Bordeaux, France
| | - J C Soria
- Cancer Medicine Department, INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | | | - A Italiano
- Département d'Innovation Précoce et d'Essais Thérapeutiques (DITEP), INSERM U1015 & CIC1428, Université Paris Saclay, Gustave Roussy, Villejuif, France; Faculty of Medicine, University of Bordeaux, Bordeaux, France; Department of Medicine, Institut Bergonié, Bordeaux, France.
| |
Collapse
|
39
|
Chargari C, Robert C, Genestie C, Deutsch E. [Precision medicine and immuno-radiotherapy]. Cancer Radiother 2021; 25:570-575. [PMID: 34391650 DOI: 10.1016/j.canrad.2021.06.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2021] [Accepted: 06/29/2021] [Indexed: 11/17/2022]
Abstract
Numerous clinical studies aim to integrate immunotherapy in radiotherapy oncology, either for generating abscopal responses in metastatic patients in combination with radiotherapy, or in the treatment of a locally advanced tumor. The search for biomarkers of response to treatment is a major axis in the development of these therapeutic combinations, to allow the early identification of patients who will benefit from the treatment, in the context of an increasingly personalized approach. We review some of the strategies that can be applied for personalization to combined radiotherapy and immunotherapy treatments.
Collapse
Affiliation(s)
- C Chargari
- Service de curiethérapie, département d'oncologie radiothérapie, Gustave Roussy Cancer Campus, Villejuif, France; Institut de recherche biomédicale des armées, Brétigny-sur-Orge, France; Radiothérapie moléculaire et thérapies innovantes, Inserm UMR1030, Gustave Roussy Cancer Campus, université Paris Saclay, Villejuif, France.
| | - C Robert
- Service de curiethérapie, département d'oncologie radiothérapie, Gustave Roussy Cancer Campus, Villejuif, France; Radiothérapie moléculaire et thérapies innovantes, Inserm UMR1030, Gustave Roussy Cancer Campus, université Paris Saclay, Villejuif, France
| | - C Genestie
- Département d'anatomopathologie, Gustave Roussy Cancer Campus, Villejuif, France
| | - E Deutsch
- Service de curiethérapie, département d'oncologie radiothérapie, Gustave Roussy Cancer Campus, Villejuif, France; Radiothérapie moléculaire et thérapies innovantes, Inserm UMR1030, Gustave Roussy Cancer Campus, université Paris Saclay, Villejuif, France
| |
Collapse
|
40
|
Robert C, Munoz A, Moreau D, Mazurier J, Sidorski G, Gasnier A, Beldjoudi G, Grégoire V, Deutsch E, Meyer P, Simon L. Clinical implementation of deep-learning based auto-contouring tools-Experience of three French radiotherapy centers. Cancer Radiother 2021; 25:607-616. [PMID: 34389243 DOI: 10.1016/j.canrad.2021.06.023] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2021] [Revised: 06/17/2021] [Accepted: 06/18/2021] [Indexed: 12/23/2022]
Abstract
Deep-learning (DL)-based auto-contouring solutions have recently been proposed as a convincing alternative to decrease workload of target volumes and organs-at-risk (OAR) delineation in radiotherapy planning and improve inter-observer consistency. However, there is minimal literature of clinical implementations of such algorithms in a clinical routine. In this paper we first present an update of the state-of-the-art of DL-based solutions. We then summarize recent recommendations proposed by the European society for radiotherapy and oncology (ESTRO) to be followed before any clinical implementation of artificial intelligence-based solutions in clinic. The last section describes the methodology carried out by three French radiation oncology departments to deploy CE-marked commercial solutions. Based on the information collected, a majority of OAR are retained by the centers among those proposed by the manufacturers, validating the usefulness of DL-based models to decrease clinicians' workload. Target volumes, with the exception of lymph node areas in breast, head and neck and pelvic regions, whole breast, breast wall, prostate and seminal vesicles, are not available in the three commercial solutions at this time. No implemented workflows are currently available to continuously improve the models, but these can be adapted/retrained in some solutions during the commissioning phase to best fit local practices. In reported experiences, automatic workflows were implemented to limit human interactions and make the workflow more fluid. Recommendations published by the ESTRO group will be of importance for guiding physicists in the clinical implementation of patient specific and regular quality assurances.
Collapse
Affiliation(s)
- C Robert
- Department of Radiotherapy, Gustave-Roussy, Villejuif, France.
| | - A Munoz
- Department of Radiotherapy, Centre Léon-Bérard, Lyon, France
| | - D Moreau
- Department of Radiotherapy, Hôpital Européen Georges-Pompidou, Paris, France
| | - J Mazurier
- Department of Radiotherapy, Clinique Pasteur-Oncorad, Toulouse, France
| | - G Sidorski
- Department of Radiotherapy, Clinique Pasteur-Oncorad, Toulouse, France
| | - A Gasnier
- Department of Radiotherapy, Gustave-Roussy, Villejuif, France
| | - G Beldjoudi
- Department of Radiotherapy, Centre Léon-Bérard, Lyon, France
| | - V Grégoire
- Department of Radiotherapy, Centre Léon-Bérard, Lyon, France
| | - E Deutsch
- Department of Radiotherapy, Gustave-Roussy, Villejuif, France
| | - P Meyer
- Service d'Oncologie Radiothérapie, Institut de Cancérologie Strasbourg Europe (Icans), Strasbourg, France
| | - L Simon
- Institut Claudius Regaud (ICR), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT-O), Toulouse, France
| |
Collapse
|
41
|
Robert C, Gasnier A, Blanchard P, Rivera S, Munoz A, Grégoire V, Deutsch E. SP-0367 Clinical validation of automatic segmentation. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)08576-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
42
|
Alvarez Andres E, Gasnier A, Veres C, Dhermain F, Corbin S, Auville F, Biron B, Vatonne A, Henry T, Estienne T, Lerousseau M, Fidon L, Deutsch E, Paragios N, Robert C. PH-0652 Synthetic CT from MRI with deep learning: Assessing the clinical impact of generated errors. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07384-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
43
|
Martinot S, Bus N, Vakalopoulou M, Robert C, Deutsch E, Paragios N. OC-0308 Fast Monte-Carlo dose simulation with recurrent deep learning. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)06855-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
44
|
Lombard A, Shreshtha K, Robert C, Roque T, Fauchon F, Noël G, Paragios N, Deutsch E. PO-1680 Synthetic-CT generation from T1w brain MRIs with a cascaded GANs ensemble approach. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)08131-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
45
|
Sun R, Lerousseau M, Henry T, Carré A, Leroy A, Estienne T, Niyoteka S, Bockel S, Rouyar A, Alvarez Andres É, Benzazon N, Battistella E, Classe M, Robert C, Scoazec JY, Deutsch É. [Artificial intelligence, radiomics and pathomics to predict response and survival of patients treated with radiations]. Cancer Radiother 2021; 25:630-637. [PMID: 34284970 DOI: 10.1016/j.canrad.2021.06.027] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2021] [Accepted: 06/19/2021] [Indexed: 12/24/2022]
Abstract
Artificial intelligence approaches in medicine are more and more used and are extremely promising due to the growing number of data produced and the variety of data they allow to exploit. Thus, the computational analysis of medical images in particular, radiological (radiomics), or anatomopathological (pathomics), has shown many very interesting results for the prediction of the prognosis and the response of cancer patients. Radiotherapy is a discipline that particularly benefits from these new approaches based on computer science and imaging. This review will present the main principles of an artificial intelligence approach and in particular machine learning, the principles of a radiomic and pathomic approach and the potential of their use for the prediction of the prognosis of patients treated with radiotherapy.
Collapse
Affiliation(s)
- R Sun
- Université Paris-Saclay, institut Gustave-Roussy, Inserm, Radiothérapie moléculaire et innovation thérapeutique, 94800 Villejuif, France; Département de radiothérapie, Gustave-Roussy Cancer Campus, 94800 Villejuif, France; Faculté de médecine, université Paris-Sud Paris-Saclay, 94270 Kremlin-Bicêtre, France.
| | - M Lerousseau
- Université Paris-Saclay, institut Gustave-Roussy, Inserm, Radiothérapie moléculaire et innovation thérapeutique, 94800 Villejuif, France
| | - T Henry
- Université Paris-Saclay, institut Gustave-Roussy, Inserm, Radiothérapie moléculaire et innovation thérapeutique, 94800 Villejuif, France; Département de médecine nucléaire, Gustave-Roussy Cancer Campus, 94800 Villejuif, France
| | - A Carré
- Université Paris-Saclay, institut Gustave-Roussy, Inserm, Radiothérapie moléculaire et innovation thérapeutique, 94800 Villejuif, France
| | - A Leroy
- Université Paris-Saclay, institut Gustave-Roussy, Inserm, Radiothérapie moléculaire et innovation thérapeutique, 94800 Villejuif, France; TheraPanacea, Paris, France
| | - T Estienne
- Université Paris-Saclay, institut Gustave-Roussy, Inserm, Radiothérapie moléculaire et innovation thérapeutique, 94800 Villejuif, France
| | - S Niyoteka
- Université Paris-Saclay, institut Gustave-Roussy, Inserm, Radiothérapie moléculaire et innovation thérapeutique, 94800 Villejuif, France
| | - S Bockel
- Département de radiothérapie, Gustave-Roussy Cancer Campus, 94800 Villejuif, France; Faculté de médecine, université Paris-Sud Paris-Saclay, 94270 Kremlin-Bicêtre, France
| | - A Rouyar
- Université Paris-Saclay, institut Gustave-Roussy, Inserm, Radiothérapie moléculaire et innovation thérapeutique, 94800 Villejuif, France
| | - É Alvarez Andres
- Université Paris-Saclay, institut Gustave-Roussy, Inserm, Radiothérapie moléculaire et innovation thérapeutique, 94800 Villejuif, France; TheraPanacea, Paris, France
| | - N Benzazon
- Université Paris-Saclay, institut Gustave-Roussy, Inserm, Radiothérapie moléculaire et innovation thérapeutique, 94800 Villejuif, France
| | - E Battistella
- Université Paris-Saclay, institut Gustave-Roussy, Inserm, Radiothérapie moléculaire et innovation thérapeutique, 94800 Villejuif, France
| | | | - C Robert
- Université Paris-Saclay, institut Gustave-Roussy, Inserm, Radiothérapie moléculaire et innovation thérapeutique, 94800 Villejuif, France; Département de radiothérapie, Gustave-Roussy Cancer Campus, 94800 Villejuif, France; Faculté de médecine, université Paris-Sud Paris-Saclay, 94270 Kremlin-Bicêtre, France
| | - J Y Scoazec
- Faculté de médecine, université Paris-Sud Paris-Saclay, 94270 Kremlin-Bicêtre, France; Département de biologie et pathologie médicales, Gustave-Roussy Cancer Campus, 94800 Villejuif, France
| | - É Deutsch
- Université Paris-Saclay, institut Gustave-Roussy, Inserm, Radiothérapie moléculaire et innovation thérapeutique, 94800 Villejuif, France; Département de radiothérapie, Gustave-Roussy Cancer Campus, 94800 Villejuif, France; Faculté de médecine, université Paris-Sud Paris-Saclay, 94270 Kremlin-Bicêtre, France
| |
Collapse
|
46
|
Meyer P, Biston MC, Khamphan C, Marghani T, Mazurier J, Bodez V, Fezzani L, Rigaud PA, Sidorski G, Simon L, Robert C. Automation in radiotherapy treatment planning: Examples of use in clinical practice and future trends for a complete automated workflow. Cancer Radiother 2021; 25:617-622. [PMID: 34175222 DOI: 10.1016/j.canrad.2021.06.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2021] [Accepted: 06/04/2021] [Indexed: 01/19/2023]
Abstract
Modern radiotherapy treatment planning is a complex and time-consuming process that requires the skills of experienced users to obtain quality plans. Since the early 2000s, the automation of this planning process has become an important research topic in radiotherapy. Today, the first commercial automated treatment planning solutions are available and implemented in a growing number of clinical radiotherapy departments. It should be noted that these various commercial solutions are based on very different methods, implying a daily practice that varies from one center to another. It is likely that this change in planning practices is still in its infancy. Indeed, the rise of artificial intelligence methods, based in particular on deep learning, has recently revived research interest in this subject. The numerous articles currently being published announce a lasting and profound transformation of radiotherapy planning practices in the years to come. From this perspective, an evolution of initial training for clinical teams and the drafting of new quality assurance recommendations is desirable.
Collapse
Affiliation(s)
- P Meyer
- Department of radiotherapy, Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France; ICUBE, CNRS UMR 7357, team IMAGES, Strasbourg, France.
| | - M-C Biston
- Department of radiotherapy, Centre Léon Bérard (CLB), Lyon, France; CREATIS, CNRS UMR5220, Inserm U1044, INSA-Lyon, Université Lyon 1, Villeurbanne, France
| | - C Khamphan
- Department of medical physics, Institut du Cancer Avignon-Provence, Avignon, France
| | - T Marghani
- Institut de radiothérapie Amethyst du Sud de l'Oise, Creil, France
| | - J Mazurier
- Centre de radiothérapie Oncorad Garonne, Toulouse, France
| | - V Bodez
- Department of medical physics, Institut du Cancer Avignon-Provence, Avignon, France
| | - L Fezzani
- Institut de radiothérapie Amethyst du Sud de l'Oise, Creil, France
| | - P A Rigaud
- Institut de radiothérapie Amethyst du Sud de l'Oise, Creil, France
| | - G Sidorski
- Centre de radiothérapie Oncorad Garonne, Toulouse, France
| | - L Simon
- Institut Claudius Regaud (ICR), Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Toulouse, France; Centre de Recherches en Cancérologie de Toulouse (CRCT), Université de Toulouse, INSERM U1037, Toulouse, France
| | - C Robert
- Université Paris-Saclay, Institut Gustave Roussy, INSERM, Radiothérapie Moléculaire et Innovation Thérapeutique, Villejuif, France; Department of Radiotherapy, Gustave Roussy, Villejuif, France
| |
Collapse
|
47
|
Forde E, Leech M, Robert C, Herron E, Marignol L. Influence of inter-observer delineation variability on radiomic features of the parotid gland. Phys Med 2021; 82:240-248. [PMID: 33677385 DOI: 10.1016/j.ejmp.2021.01.084] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/05/2020] [Revised: 01/06/2021] [Accepted: 01/29/2021] [Indexed: 12/14/2022] Open
Abstract
PURPOSE This study aimed to quantify the variability in the values of radiomic features extracted from a right parotid gland (RPG) delineated by a series of independent observers. METHODS This was a secondary analysis of anonymous data from a delineation workshop. Inter-observer variability of the RPG from 40 participants was quantified using DICE similarity coefficient (DSC) and Hausdorff distance (HD). An additional contour was generated using Varian SmartSegmentation. Radiomic features extracted include four shape features, six histogram features, and 32 texture features. The absolute mean paired percentage difference (PPD) in feature values from the expert and participants were ranked . Feature robustness was classified using pre- determined thresholds. RESULTS 63% of participants achieved a DSC > 0.7, the auto- segmentation DSC was 0.76. The average HD for the participants was 16.16 mm ± 0.66 mm, and 15.16 mm for the auto-segmentation. 48% (n = 20) and 33% (n = 14) of features were deemed to be robust with a mean absolute PPD < 5%, for the auto-segmentation and manual delineations respectively; the majority of which were from the grey-run length matrix family. 7% (n = 3) of features from the auto- segmentation and 10% (n = 4) from the manual contours were deemed to be unstable with a mean absolute PPD > 50%. The value of the most robust feature was not related to DSC and HD. CONCLUSION Inter-observer delineation variability affects the value of the radiomic features extracted from the RPG. This study identifies the radiomic features least sensitive to these uncertainties. Further investigation of the clinical relevance of these features in prediction of xerostomia is warranted.
Collapse
Affiliation(s)
- E Forde
- Applied Radiation Therapy Trinity, Discipline of Radiation Therapy, Trinity St James' Cancer Institute, Trinity College Dublin, Dublin, Ireland.
| | - M Leech
- Applied Radiation Therapy Trinity, Discipline of Radiation Therapy, Trinity St James' Cancer Institute, Trinity College Dublin, Dublin, Ireland
| | - C Robert
- Molecular Radiotherapy and Innovative Therapeutics, INSERM UMR1030, Gustave Roussy Cancer Campus, Université Paris Salcay, Villejuif, France
| | - E Herron
- Department of Psychiatry School of Medicine, Trinity College Dublin, Dublin, Ireland
| | - L Marignol
- Applied Radiation Therapy Trinity, Discipline of Radiation Therapy, Trinity St James' Cancer Institute, Trinity College Dublin, Dublin, Ireland
| |
Collapse
|
48
|
Gkotsi A, Bourdon C, Robert C, Schuind F. Normative values of the DASH questionnaire in healthy individuals over 50 years of age. Hand Surg Rehabil 2021; 40:258-262. [PMID: 33636383 DOI: 10.1016/j.hansur.2020.12.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/22/2020] [Revised: 12/07/2020] [Accepted: 12/11/2020] [Indexed: 11/25/2022]
Abstract
This study aimed to define the normative values of the DASH score in healthy individuals over 50 years of age. One hundred and twenty subjects equally representing both genders and six age categories (50-54, 55-59, 60-64, 65-69, 70-74 and 75-80 years), with no past medical history affecting the upper limb, were asked to complete the DASH questionnaire. A visual analogue scale for pain and an HAQ-DI questionnaire were also completed to confirm the absence of symptomatic untreated upper limb pathologies. In this series of a priori normal subjects, most had a DASH score greater than 0. Moreover, the DASH score was found to rise with age, with a statistically significant difference between women and men. The DASH questionnaire is widely accepted in the everyday medical practice as a tool to evaluate upper limb function. However, age adjustment of the DASH questionnaire is necessary to correctly evaluate the clinical status and progression of individuals over the age of 50.
Collapse
Affiliation(s)
- A Gkotsi
- Department of Orthopaedics and Traumatology, Cliniques Universitaires de Bruxelles, Hôpital Erasme, Université Libre de Bruxelles, Route de Lennik 808, 1070 Brussels, Belgium.
| | - C Bourdon
- Physiotherapy and Rehabilitation Department, Cliniques Universitaires de Bruxelles, Hôpital Erasme, Université Libre de Bruxelles, Route de Lennik 808, 1070 Brussels, Belgium
| | - C Robert
- Physiotherapy and Rehabilitation Department, Cliniques Universitaires de Bruxelles, Hôpital Erasme, Université Libre de Bruxelles, Route de Lennik 808, 1070 Brussels, Belgium
| | - F Schuind
- Department of Orthopaedics and Traumatology, Cliniques Universitaires de Bruxelles, Hôpital Erasme, Université Libre de Bruxelles, Route de Lennik 808, 1070 Brussels, Belgium
| |
Collapse
|
49
|
Robert C, Dery H, Ren L, Van Tuan D, Courtade E, Yang M, Urbaszek B, Lagarde D, Watanabe K, Taniguchi T, Amand T, Marie X. Measurement of Conduction and Valence Bands g-Factors in a Transition Metal Dichalcogenide Monolayer. Phys Rev Lett 2021; 126:067403. [PMID: 33635701 DOI: 10.1103/physrevlett.126.067403] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/06/2020] [Accepted: 12/03/2020] [Indexed: 06/12/2023]
Abstract
The electron valley and spin degree of freedom in monolayer transition-metal dichalcogenides can be manipulated in optical and transport measurements performed in magnetic fields. The key parameter for determining the Zeeman splitting, namely, the separate contribution of the electron and hole g factor, is inaccessible in most measurements. Here we present an original method that gives access to the respective contribution of the conduction and valence band to the measured Zeeman splitting. It exploits the optical selection rules of exciton complexes, in particular the ones involving intervalley phonons, avoiding strong renormalization effects that compromise single particle g-factor determination in transport experiments. These studies yield a direct determination of single band g factors. We measure g_{c1}=0.86±0.1, g_{c2}=3.84±0.1 for the bottom (top) conduction bands and g_{v}=6.1±0.1 for the valence band of monolayer WSe_{2}. These measurements are helpful for quantitative interpretation of optical and transport measurements performed in magnetic fields. In addition, the measured g factors are valuable input parameters for optimizing band structure calculations of these 2D materials.
Collapse
Affiliation(s)
- C Robert
- Université de Toulouse, INSA-CNRS-UPS, LPCNO, 135 Avenue de Rangueil, 31077 Toulouse, France
| | - H Dery
- Department of Electrical and Computer Engineering, University of Rochester, Rochester, New York 14627, USA
- Department of Physics, University of Rochester, Rochester, New York 14627, USA
| | - L Ren
- Université de Toulouse, INSA-CNRS-UPS, LPCNO, 135 Avenue de Rangueil, 31077 Toulouse, France
| | - D Van Tuan
- Department of Electrical and Computer Engineering, University of Rochester, Rochester, New York 14627, USA
| | - E Courtade
- Université de Toulouse, INSA-CNRS-UPS, LPCNO, 135 Avenue de Rangueil, 31077 Toulouse, France
| | - M Yang
- Department of Electrical and Computer Engineering, University of Rochester, Rochester, New York 14627, USA
| | - B Urbaszek
- Université de Toulouse, INSA-CNRS-UPS, LPCNO, 135 Avenue de Rangueil, 31077 Toulouse, France
| | - D Lagarde
- Université de Toulouse, INSA-CNRS-UPS, LPCNO, 135 Avenue de Rangueil, 31077 Toulouse, France
| | - K Watanabe
- National Institute for Materials Science, Tsukuba, Ibaraki 305-004, Japan
| | - T Taniguchi
- National Institute for Materials Science, Tsukuba, Ibaraki 305-004, Japan
| | - T Amand
- Université de Toulouse, INSA-CNRS-UPS, LPCNO, 135 Avenue de Rangueil, 31077 Toulouse, France
| | - X Marie
- Université de Toulouse, INSA-CNRS-UPS, LPCNO, 135 Avenue de Rangueil, 31077 Toulouse, France
| |
Collapse
|
50
|
Plante-Dubé M, Picard C, Gilbert I, Robert C, Fievez V, Vlaeminck B, Belleannée C, Gervais R, Chouinard PY. Effects of a dietary supplement enriched in palmitoleic acid on fatty acid composition of follicular fluid, granulosa cell metabolism, and oocyte developmental capacity in early lactation dairy cows. J Dairy Sci 2021; 104:3693-3706. [PMID: 33455772 DOI: 10.3168/jds.2020-19191] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Accepted: 10/19/2020] [Indexed: 01/22/2023]
Abstract
In high-yielding dairy cows, some fertility traits can be influenced by the fatty acid (FA) composition of the follicular fluid during early lactation. The first objective of the current study was to evaluate the potential of dietary supplements enriched in specific FA to influence the FA composition of follicular fluid lipid classes in early lactation dairy cows. The second objective was to determine the influence of the resulting follicular fluid FA composition on the folliculogenesis, lipid and energy metabolism of granulosa cells, as well as oocyte quality and embryo development. Twenty Holstein multiparous cows in late gestation were randomly assigned to 200 g/d of FA supplements enriched in (1) palmitic acid (control treatment; 82% 16:0; PA) in the rumen or (2) palmitoleic acid (sea buckthorn oil; 27% cis-9 16:1, 28% 16:0, 22% cis-9 18:1, and 11% cis-9,cis-12 18:2; SBT) in the abomasum. The treatment period ranged from 20 ± 5 d precalving to 67 ± 2 d postcalving. Cumulus-oocyte complexes, granulosa cells, and follicular fluid were recovered from 2 sequential sessions of ovum pick-up (OPU-1 and OPU-2) at 46 and 67 ± 2 d postcalving (mean ± standard deviation). On the same days, blood samples were collected. Milk performance was recorded, and feed and milk samples were collected from d 8 to 10 ± 3 (onset of lactation), d 35 to 37 ± 2 (before OPU-1), and d 63 to 65 ± 2 (before OPU-2). Treatments did not affect milk yield or fat concentration throughout the experimental trial. Compared with PA, SBT increased the cis-9 16:1 concentration in milk fat, in plasma esterified lipid classes (phospholipids, cholesterol esters, and triacylglycerols), and in follicular fluid phospholipids and cholesterol esters at OPU-1. Abundance of mRNA for stearoyl-CoA desaturase 1 and 5, and perilipin 2 in granulosa cells was not different between treatments, but an increase in the level of stearoyl-CoA desaturase 5 was observed between the 2 OPU periods. Treatments did not affect oocyte quality and developmental capacity or embryo lipid metabolism when cultivated in vitro. These results suggest that limited modifications in the FA composition of the oocyte microenvironment via dietary lipid supplements enriched in specific FA had no major effects on granulosa cell metabolism and oocyte developmental capacity in early lactation cows.
Collapse
Affiliation(s)
- M Plante-Dubé
- Département des Sciences Animales, Université Laval, Québec, QC, G1V 0A6, Canada; Institute of Nutrition and Functional Food, Université Laval, Québec, QC, G1V 0A6, Canada
| | - C Picard
- Département des Sciences Animales, Université Laval, Québec, QC, G1V 0A6, Canada; Institute of Nutrition and Functional Food, Université Laval, Québec, QC, G1V 0A6, Canada
| | - I Gilbert
- Institute of Nutrition and Functional Food, Université Laval, Québec, QC, G1V 0A6, Canada
| | - C Robert
- Département des Sciences Animales, Université Laval, Québec, QC, G1V 0A6, Canada; Institute of Nutrition and Functional Food, Université Laval, Québec, QC, G1V 0A6, Canada
| | - V Fievez
- Department of Animal Production, Ghent University, East Flanders, 2PWG+GW, Belgium
| | - B Vlaeminck
- Department of Animal Production, Ghent University, East Flanders, 2PWG+GW, Belgium
| | - C Belleannée
- Département d'Obstétrique, de Gynécologie et de Reproduction, Université Laval, Québec, QC, G1V 0A6, Canada
| | - R Gervais
- Département des Sciences Animales, Université Laval, Québec, QC, G1V 0A6, Canada.
| | - P Y Chouinard
- Département des Sciences Animales, Université Laval, Québec, QC, G1V 0A6, Canada; Institute of Nutrition and Functional Food, Université Laval, Québec, QC, G1V 0A6, Canada.
| |
Collapse
|